Thursday, April 18, 2024
4/18/2024
PROJECT SUMMARY/ABSTRACT Anti-CTLA-4 was first immune checkpoint blockade therapy approved by the FDA to treat patients with cancer. Notwithstanding its impressive clinical response in ~20% of patients with advanced melanoma, there is a clear need to improve its efficacy. We recently showed that loss of IFN-¿ signaling genes could partially explain why the remaining ~80% patients are resistance to anti-CTLA-4 therapy. Therefore, identifying novel therapeutic targets/approaches capable of overcoming resistance and boosting efficacy of anti-CTLA-4 is of utmost importance We and others previously demonstrated that the HIF1¿-glycolysis axis orchestrates an essential “metabolic checkpoint” in driving effector T cell differentiation and in suppressing regulatory T cell induction, two functional outcomes closely associated with anti-CTLA-4 efficacy, suggesting activating HIF1¿ and glycolysis in T cells could represent an effective approach to improve therapeutic efficacy of anti-CTLA-4. To this end, we have generated interesting preliminary data showing that anti-CTLA-4 selectively upregulates HIF1¿ and its downstream targets, glycolytic enzymes in tumor-infiltrating T cells (TILs). And, specific deletion of HIF1¿ in T cells and simultaneous inhibition of glycolysis largely abolishes the therapeutic effects of anti-CTLA-4, pointing to a critical role of HIF1¿ and glycolysis in this therapy. Therefore, we propose that HIF1¿, via modulating glycolytic activity of TILs, dictates therapeutic efficacy of anti-CTLA-4, which can serve as novel therapeutic targets to promote efficacy of anti-CTLA-4. In Aim 1, we will characterize how T cell-intrinsic HIF1¿ governs glycolytic activity and effector functions of TILs in response to anti-CTLA-4. In Aim 2, we will target the HIF1¿- glycolysis pathway to promote therapeutic efficacy of anti-CTLA-4. While it is well-known that anti-CTLA-4 markedly rejuvenates effector functions of TILs, the specific underlying mechanisms are largely unknown. Insights gained from these studies will significantly advance our understanding of how anti-CTLA-4 metabolically augments anti-tumor responses and manifest novel therapeutic opportunities (e.g., targeting metabolic pathways) to improve efficacy of anti-CTLA-4.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
